## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3400228/publications.pdf Version: 2024-02-01



KE CHEN

#	Article	IF	CITATIONS
1	OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers. Nucleic Acids Research, 2022, 50, D1340-D1347.	6.5	22
2	Preliminary assessment of a portable Raman spectroscopy system for post-operative urinary stone analysis. World Journal of Urology, 2022, 40, 229-235.	1.2	4
3	YTHDF1 promotes mRNA degradation via YTHDF1â€AGO2 interaction and phase separation. Cell Proliferation, 2022, 55, e13157.	2.4	36
4	Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review. Cancers, 2022, 14, 866.	1.7	5
5	Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radical Biology and Medicine, 2022, 184, 135-147.	1.3	24
6	Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis. Bioactive Materials, 2021, 6, 963-974.	8.6	73
7	ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics, 2021, 11, 841-860.	4.6	51
8	Pit latrines may be a potential risk in rural China and low-income countries when dealing with COVID-19. Science of the Total Environment, 2021, 761, 143283.	3.9	12
9	Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy. Molecular Oncology, 2021, 15, 1764-1782.	2.1	17
10	MMP9 and IGFBP1 Regulate Tumor Immune and Drive Tumor Progression in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2021, 12, 2243-2257.	1.2	15
11	Identification of KIF20A as a tumor biomarker and forwarder of clear cell renal cell carcinoma. Chinese Medical Journal, 2021, 134, 2137-2139.	0.9	5
12	NNTâ€induced tumor cell "slimming―reverses the proâ€carcinogenesis effect of HIF2a in tumors. Clinical and Translational Medicine, 2021, 11, e264.	1.7	13
13	The Role of Dyslipidemia in Colitis-Associated Colorectal Cancer. Journal of Oncology, 2021, 2021, 1-13.	0.6	5
14	Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma. Cancer Communications, 2021, 41, 316-332.	3.7	7
15	SLC39A8/Zinc Suppresses the Progression of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 651921.	1.3	5
16	Integrative Analysis of Methylation and Copy Number Variations of Prostate Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis. Frontiers in Oncology, 2021, 11, 647253.	1.3	7
17	Comprehensive characterization of alternative splicing in renal cell carcinoma. Briefings in Bioinformatics, 2021, 22, .	3.2	11
18	Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1–Mediated Immune Evasion in Prostate Cancer. Cancer Immunology Research, 2021, 9, 838-852.	1.6	12

#	Article	IF	CITATIONS
19	SARS-CoV-2 Causes Acute Kidney Injury by Directly Infecting Renal Tubules. Frontiers in Cell and Developmental Biology, 2021, 9, 664868.	1.8	24
20	METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 609174.	1.1	11
21	CD46 splice variant enhances translation of specific mRNAs linked to an aggressive tumor cell phenotype in bladder cancer. Molecular Therapy - Nucleic Acids, 2021, 24, 140-153.	2.3	11
22	Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1. Clinical and Translational Medicine, 2021, 11, e449.	1.7	22
23	Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study. Infectious Diseases and Therapy, 2021, 10, 421-438.	1.8	9
24	Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miRâ€133b. Journal of Cellular Physiology, 2020, 235, 1235-1246.	2.0	39
25	MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine, 2020, 51, 102622.	2.7	59
26	Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. Theranostics, 2020, 10, 11444-11461.	4.6	14
27	Endogenous Cyclin D1 Promotes the Rate of Onset and Magnitude of Mitogenic Signaling via Akt1 Ser473 Phosphorylation. Cell Reports, 2020, 32, 108151.	2.9	9
28	Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nature Communications, 2020, 11, 5077.	5.8	281
29	<p>Identification of <em>PDE7B</em> as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma</p> . Cancer Management and Research, 2020, Volume 12, 5701-5712.	0.9	5
30	The membrane-associated form of cyclin D1 enhances cellular invasion. Oncogenesis, 2020, 9, 83.	2.1	16
31	CircRNA inhibits DNA damage repair by interacting with host gene. Molecular Cancer, 2020, 19, 128.	7.9	198
32	The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma. Frontiers in Genetics, 2020, 11, 602485.	1.1	23
33	PINK1 Activation and Translocation to Mitochondria-Associated Membranes Mediates Mitophagy and Protects Against Hepatic Ischemia/Reperfusion Injury. Shock, 2020, 54, 783-793.	1.0	24
34	Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes. Molecular Therapy, 2020, 28, 1658-1672.	3.7	109
35	Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolismâ€mediated mitochondrial quality control. FASEB Journal, 2020, 34, 6198-6214.	0.2	6
36	The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 1712-1726.	1.2	5

#	Article	IF	CITATIONS
37	Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death and Disease, 2020, 11, 515.	2.7	70
38	Pivotal biomarker expression and drug screening in advanced ccRCC. Clinical and Translational Medicine, 2020, 10, e114.	1.7	4
39	Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition. Journal of Cancer, 2020, 11, 1151-1161.	1.2	7
40	Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression. Annals of Translational Medicine, 2020, 8, 319-319.	0.7	18
41	IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors. Molecular Therapy, 2020, 28, 1299-1313.	3.7	20
42	Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 1516-1528.	3.2	34
43	The Identification of Key Gene Expression Signature in Prostate Cancer. Critical Reviews in Eukaryotic Gene Expression, 2020, 30, 153-168.	0.4	3
44	ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma. Aging, 2020, 12, 1808-1827.	1.4	25
45	LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation. Aging, 2020, 12, 17459-17479.	1.4	10
46	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). Oncology Letters, 2020, 20, 1-1.	0.8	19
47	CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. Journal of Cancer Research and Therapeutics, 2020, 16, 990.	0.3	4
48	Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers. Oncogene, 2019, 38, 6678-6695.	2.6	58
49	Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis. Biomedicine and Pharmacotherapy, 2019, 118, 109264.	2.5	30
50	RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma. International Journal of Oncology, 2019, 55, 645-656.	1.4	20
51	KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the regulation of hepatocellular carcinoma microvascular invasion by regulating epithelial-mesenchymal transition. Journal of Cancer, 2019, 10, 3501-3516.	1.2	36
52	Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning. Journal of Pineal Research, 2019, 67, e12607.	3.4	57
53	pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. Genome Medicine, 2019, 11, 67.	3.6	53
54	Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma. BMC Cancer, 2019, 19, 874.	1.1	7

#	Article	IF	CITATIONS
55	Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunology Research, 2019, 7, 1135-1147.	1.6	46
56	Regulatory Network of Two Tumor-Suppressive Noncoding RNAs Interferes with the Growth and Metastasis of Renal Cell Carcinoma. Molecular Therapy - Nucleic Acids, 2019, 16, 554-565.	2.3	17
57	The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer. Journal of Cancer, 2019, 10, 1398-1408.	1.2	24
58	Tumor Cell "Slimming―Regulates Tumor Progression through PLCL1/UCP1â€Mediated Lipid Browning. Advanced Science, 2019, 6, 1801862.	5.6	32
59	Genome-wide identification of cancer-specific alternative splicing in circRNA. Molecular Cancer, 2019, 18, 35.	7.9	61
60	High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. Experimental Cell Research, 2019, 376, 181-191.	1.2	6
61	LXRα promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma. Cell Death and Disease, 2019, 10, 159.	2.7	30
62	The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets. Journal of Cellular Physiology, 2019, 234, 15607-15618.	2.0	30
63	Renalase Attenuates Mouse Fatty Liver Ischemia/Reperfusion Injury through Mitigating Oxidative Stress and Mitochondrial Damage via Activating SIRT1. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-21.	1.9	31
64	The screening of pivotal gene expression signatures and biomarkers in renal carcinoma. Journal of Cancer, 2019, 10, 6384-6394.	1.2	3
65	Protective Role of mTOR in Liver Ischemia/Reperfusion Injury: Involvement of Inflammation and Autophagy. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-17.	1.9	27
66	Oleic Acid Protects against Hepatic Ischemia and Reperfusion Injury in Mice by Inhibiting AKT/mTOR Pathways. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-18.	1.9	8
67	Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer. Medical Science Monitor, 2019, 25, 193-239.	0.5	18
68	A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma. Aging, 2019, 11, 9597-9615.	1.4	31
69	Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. BMC Cancer, 2018, 18, 88.	1.1	36
70	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 529-539.	1.6	30
71	CSCD: a database for cancer-specific circular RNAs. Nucleic Acids Research, 2018, 46, D925-D929.	6.5	300
72	RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. Experimental Cell Research, 2018, 372, 118-128.	1.2	14

#	Article	IF	CITATIONS
73	Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. International Journal of Oncology, 2018, 53, 137-147.	1.4	49
74	PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e9-343.e19.	0.8	27
75	MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Cellular Physiology and Biochemistry, 2018, 48, 801-814.	1.1	72
76	Upregulation of MIAT Regulates LOXL2 Expression by Competitively Binding MiR-29c in Clear Cell Renal Cell Carcinoma. Cellular Physiology and Biochemistry, 2018, 48, 1075-1087.	1.1	48
77	Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. OncoTargets and Therapy, 2018, Volume 11, 3167-3178.	1.0	26
78	DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biology, 2018, 19, 80.	3.8	285
79	Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma. Tumor Biology, 2017, 39, 101042831769911.	0.8	11
80	Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. Oncology Reports, 2017, 37, 3651-3659.	1.2	4
81	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends in Pharmacological Sciences, 2017, 38, 1041-1051.	4.0	12
82	Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. Cellular Physiology and Biochemistry, 2017, 43, 2420-2433.	1.1	99
83	Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma. Experimental Cell Research, 2017, 358, 269-278.	1.2	30
84	Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clinical Cancer Research, 2017, 23, 3428-3441.	3.2	109
85	Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition. International Journal of Oncology, 2017, 51, 336-346.	1.4	36
86	lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. Oncotarget, 2017, 8, 85353-85367.	0.8	55
87	MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells. Oncotarget, 2017, 8, 103261-103273.	0.8	19
88	Long non-coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 113622-113634.	0.8	33
89	Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 94819-94833.	0.8	8
90	Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. Cell Reports, 2016, 15, 2214-2225.	2.9	45

#	Article	IF	CITATIONS
91	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nature Communications, 2016, 7, 11406.	5.8	245
92	miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. Cancer Letters, 2016, 374, 107-116.	3.2	60
93	Regulation of glucose metabolism by p62/SQSTM1 through HIF1α. Journal of Cell Science, 2016, 129, 817-30.	1.2	22
94	miRâ€490â€5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biology of the Cell, 2016, 108, 41-50.	0.7	56
95	Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. Cancer Research, 2016, 76, 329-338.	0.4	39
96	Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Clinical Cancer Research, 2016, 22, 1531-1544.	3.2	24
97	The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Scientific Reports, 2015, 5, 13528.	1.6	24
98	Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo. Journal of Experimental and Clinical Cancer Research, 2015, 34, 21.	3.5	60
99	The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module. Cancer Research, 2015, 75, 1992-2004.	0.4	34
100	Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria. American Journal of Pathology, 2015, 185, 266-279.	1.9	51
101	miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ. Oncotarget, 2015, 6, 4144-4158.	0.8	58
102	ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer. Oncotarget, 2015, 6, 6959-6976.	0.8	23
103	MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget, 2015, 6, 13201-13215.	0.8	47
104	MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget, 2015, 6, 26457-26471.	0.8	70
105	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget, 2015, 6, 38005-38015.	0.8	192
106	Cell Fate Factor DACH1 Represses YB-1–Mediated Oncogenic Transcription and Translation. Cancer Research, 2014, 74, 829-839.	0.4	68
107	Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression. Molecular Cancer Therapeutics, 2014, 13, 3086-3097.	1.9	199
108	Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling. Cancer Research, 2014, 74, 3959-3970.	0.4	32

#	Article	IF	CITATIONS
109	The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget, 2014, 5, 3611-3621.	0.8	39
110	CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget, 2014, 5, 10293-10306.	0.8	52
111	Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33, 786-790.	1.0	0
112	Dachshund Binds p53 to Block the Growth of Lung Adenocarcinoma Cells. Cancer Research, 2013, 73, 3262-3274.	0.4	55
113	Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer. Oncotarget, 2013, 4, 923-935.	0.8	27
114	Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 697-699.	1.0	6